the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) …
Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs Read more »
October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 …
Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors? Read more »
April o5, 2016 – There have been indications that a heightened risk of heart failure may be associated with diabetes medications containing the pharmacologically active ingredients saxagliptin or alogliptin. In the US, this includes the FDA-approved drugs Saxagliptin (Onglyza), Saxagliptin/Metformin …